Improving Business Performance through Innovation Strategy and Total Quality Management Practice: Survey on the Pharmaceutical Industry in Indonesia

Yuli Fitriyani, Yudi Aziz, Irvan Rivani, Umi Kaltum, John Sihotang

Abstract

The main purpose of this research is to analyze the relationship between innovation strategy and Total Quality Management (TQM) in improving business performance. The object of study of this research is the pharmaceutical Industries in Indonesia. This research reveals the proper innovation strategy execution and effective implementation of TQM in business performance improvement. In this context, data collected from 168 managers at 42 firms operating in the pharmaceutical industry in Indonesia were analyzed. The partial least squares structural equation modeling (PLS-SEM) method is used to test the hypotheses both of reflective and formative construct with second-order/higher-order construct in our model of study which is rarely found in the previous study. The findings support the hypothesis that there is a positive and significant effect of innovation strategy and TQM on improving the business performance of the company. The result of this research will have strategic implications for the company and expect to be used as feedback related to the execution of their innovation strategies and TQM implementation promptly to improve their business performance.

Keywords: innovation strategy, total quality management, business performance, strategic management, happiness at work, work motivation, employee performance

1. INTRODUCTION

Today, the pharmaceutical industry in Indonesia is one of the priority sectors because it is considered to provide a significant contribution to the growth of the Indonesian economy. The pharmaceutical industry market grew 7.5% until the fourth quarter of 2016, higher than the same period in the previous year which was 4.9% (Kalbe Farma, 2018).

One of the driving factors for pharmaceutical industry growth is the widespread participation of the National Health Insurance (Jaminan Kesehatan Nasional/JKN) or BPJS (Badan Penyelenggara Jaminan Sosial kesehatan). JKN is health protection program provided by the Indonesian Government that covered basic health needs given to everyone who has paid contributions or fees paid by the government. This program aims to provide health insurance for all Indonesians and expatriates working in Indonesia for more than 6 months.

JKN program will continue to be the main driver for the development of the healthcare and pharmaceutical industries,
where the health industries continue to record growth in the number of BPJS Kesehatan participants which reached around 199 million in July 2018. This is in line with the initial plan of the JKN program which targeted 100% coverage in 2019 for the entire Indonesian population of 250 million.

Even though pharmaceutical industry growth is increasing, however, its growth in 2016 was lower compared to the compound annual growth rate (CAGR) growth in 2012-2016 worth 8.9%. This is caused by the JKN implementation. In terms of quantity, medicine consumption has indeed increased, but sales have decreased, since most medicine used in JKN program was generic drugs which selling price has been set by the government through the Government Agency for Procurement of Goods and Services Policy, meanwhile the price is not negotiable. Some pharmaceutical industries in Indonesia face a slowdown in business growth. For example, PT Kalbe Farma Tbk, they experienced a slowdown in business growth from the 2014-2016 period reaching 14.7%. However, in 2016-2017 the company’s sales growth was only around 4.5% (Kalbe Farma, 2018).

Most of the generic drugs sold under the JKN program are cheaper so that they cannot drive sales much higher for the company. Other causes are 90% of raw materials for medicine production originating from imports and high cost of distribution. Pharmaceutical companies must distribute their medicines to remote areas far from factories with the same selling price because they are participating in the JKN program. New challenges for the pharmaceutical industry in Indonesia in the JKN system implementation era are able to produce cheap medicines but still, the quality should be guaranteed. To obtain marketing authorization, medicinal products should meet the standards of quality, efficacy, and safety that have been determined in accordance with the regulation of Good Manufacturing Practices (GMP).

This phenomenon raises questions about key success factors related to the effectiveness of corporate strategies that must be implemented in order to survive and grow sustainably with the change in the business landscape of the pharmaceutical industry which is currently undergoing changes to the insurance market, namely producing generic drugs at low prices (low cost and low margin medicines). To overcome these challenges, while ensuring sustainable growth of the pharmaceutical industry in Indonesia, an innovation strategy in terms of research and development and industrial raw materials are needed as an opportunity for improving business in the pharmaceutical industries. Innovation can have a significant impact on the performance of a company’s business through better market share, thus increasing the competitiveness of the company and ultimately will have an impact on improving its business performance. In today’s competitive world, it is concluded that using old methods will not be efficient anymore. New technology and product innovation are some new techniques that are currently considered to be implemented globally in order to survive in the competition (Tohidi and Jabbari, 2012).

Innovation has played a significant role in creating unique products and services, in order to get value-added for the company and then determine constraints to entry for new rivals (Antunes et al., 2017). However, the company is impossible to get avail from the innovation advantages if there is no organizational structure that is deemed qualified to follow these strategies. Based on these reasons, innovation has triggered the interest of many researchers to identify the driving factors, and one of the problems that have been considered is whether the practice of TQM can emerge as one of the supporting factors of the innovation strategy. The intense global competition has had an impact on the development of TQM concept (Ahmad et al., 2012).

In the literature, it can be found opposite ideas, and that is why there is no consensus about whether innovation creates conditions for the application of TQM or TQM actually helps create an environment and culture to support innovation (Antunes et al., 2017). One of the goals of this research is to contribute in an enriching way to the study of these variables, based on Indonesian pharmaceutical companies. Thus, it is intended in this research to analyze the relationship between innovation strategy and TQM in improving business performance. Furthermore, we use both of reflective and formative constructs with second-order/higher-order construct in our model of study which is rarely found in the previous study.

The result of this research will have strategic implications for the company and expect to be used as feedback related to the execution of their innovation strategies and TQM implementation promptly to improve their business performance.

2. LITERATURE REVIEW

Several previous studies regarding the role of innovation strategy on the company’s business performance showed a positive relationship between the two from various dimensions, for example, Al-Battaineh (2018) revealed that product innovation, process innovation, and innovation management had a positive influence on improving the company’s business performance. Other researchers also argued that process innovation and product innovation have a positive impact on a company’s
has triggered the interest of many researchers to identify and defining entry barriers for new entrants. For this reason, in-

2.1. Innovation Strategy and TQM

pany’s business performance and creating sustainable growth.

prove their competitive advantage, thus improving the com-

used as feedback for companies related to the execution of their

implementation, and business performance of the pharmaceuti-

the current situation of the innovation strategy execution, TQM

performance. One of the goals of this research is to contribute

tify the drivers, and one of the issues that have been considered

whether the practice of TQM can emerge as one of the fac-

rity management practice to-

increase knowledge, and continue to improve their systems and

relationship with innovation. This practice can train experts and specialists in research and

performance. Whereas Martínez-Costa et al. (2008) revealed different results, that TQM culture has a direct influence on improving the process and product design capabilities but does not affect product innovation. Other researchers’ opinions support the negative relationship between TQM and innovation performance claimed that TQM can make organizations think narrowly and inhibit creativity because of the standardization practice (Zehir et al., 2012).

An empirical study conducted by Zehir et al. (2012) con-
firmed the positive relationship between TQM and innovation performance. Whereas Martínez-Costa et al. (2008) revealed different results, that TQM culture has a direct influence on improving the process and product design capabilities but does not affect product innovation. Other researchers’ opinions support the negative relationship between TQM and innovation performance claimed that TQM can make organizations think narrowly and inhibit creativity because of the standardization practice (Zehir et al., 2012).

Meanwhile, Juran (2001) stated that one of TQM dimen-
sion, namely customer orientation has a significant positive re-
lationship to innovation because customer focus can encourage companies to always meet the customer’s needs and desires so that the company can survive in a competitive business environment. To clarify the issue in previous studies, the author is interested in conducting further investigation on the relationship between innovation strategy and TQM associated with business performance. One of the goals of this research is to contribute in an enriching way for the study of these variables to capture the current situation of the innovation strategy execution, TQM implementation, and business performance of the pharmaceuti-
cal industry in Indonesia today. This research is expected to be used as feedback for companies related to the execution of their innovation strategies and TQM implementation promptly to improve their competitive advantage, thus improving the company’s business performance and creating sustainable growth.

2.1. Innovation Strategy and TQM

Innovation plays a very important role in providing unique products and services, creating value-added for the company, and defining entry barriers for new entrants. For this reason, innovation has triggered the interest of many researchers to iden-

Table 1: Sales Growth of Pharmaceutical Industries in Indonesia

<table>
<thead>
<tr>
<th>No</th>
<th>Company Name</th>
<th>2016-2017 Growth</th>
<th>2015-2016 Growth</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>PT Darya-Varia Laboratoria Tbk</td>
<td>8.56%</td>
<td>11.12%</td>
</tr>
<tr>
<td>2</td>
<td>PT Kimia Farma (Persero) Tbk</td>
<td>5.44%</td>
<td>19.6%</td>
</tr>
<tr>
<td>3</td>
<td>PT Kalbe Farma Tbk</td>
<td>4.17%</td>
<td>8.3%</td>
</tr>
<tr>
<td>4</td>
<td>PT Industri Jamu dan Farmasi Sido Muncul Tbk</td>
<td>0.47%</td>
<td>55.2%</td>
</tr>
<tr>
<td>5</td>
<td>PT Tempo Scan Pacific Tbk</td>
<td>4.68%</td>
<td>11.7%</td>
</tr>
<tr>
<td>6</td>
<td>PT Indoarma (Persero) Tbk</td>
<td>-2.59%</td>
<td>3.3%</td>
</tr>
<tr>
<td>7</td>
<td>PT Millennium Pharmacor International Tbk</td>
<td>7.14%</td>
<td>15.4%</td>
</tr>
<tr>
<td>8</td>
<td>PT Merck Sharp Dohme Tbk</td>
<td>-8.97%</td>
<td>38.9%</td>
</tr>
</tbody>
</table>

Source: Company’s Financial Statement in Year 2016-2017
ing the process and product design capabilities but does not affect product innovation. Other researchers’ opinions support the negative relationship between TQM and innovation performance claimed that TQM can make organizations think narrowly and inhibit creativity because of the standardization practice (Martínez-Costa et al., 2008).

2.2. Innovation Strategy and Business Performance

Many studies revealed that innovation has played an important role in social and economic development and increases the competitiveness of companies. Innovation, like the terms used in business, are intended to describe new products, services, methods, and organizational approaches that enhance competitiveness of the company. The results of the Global Innovation survey conducted by the Boston Consulting Group (BCG) in 2014 revealed that innovation is the top 3 priority for three quarters of companies in the world. As many as 75% of respondents stated that investment in terms of innovation is primarily aimed at long-term benefits and the current competitive advantage that the company cares about (Wheelan et al., 2018).

Innovation strategy is a plan to increase market share or company profits through product and service innovation. When looking at innovation strategy through the eyes of the work that must be done, it appears that the strategy must be effective and correctly inform the executors of work, jobs, and which segments are targeted to achieve the highest growth, as well as unmet targets to give our customers better products. The innovation strategy, in the simplest terms, is to choose the most appropriate strategy among possible alternative options and develop the most appropriate type of action that is possible to be implemented at present (Al-Battaineh, 2018). The theory of innovation strategy stated that companies that have good business performance are constantly reviewing their products and services (their offerings), modifying their existing ones and developing something new in order to meet customers need better that previously unmet (David and David, 2017).

Previous studies regarding the role of innovation strategy on the company’s business performance showed a positive relationship between them from various dimensions, for example Al-Battaineh (2018) revealed that product innovation, process innovation, and innovation management had a positive influence in improving the company’s business performance. Other researchers, Beyene et al. (2016) explained that innovation strategy are positively related to product innovation performance. Whereas Riyadi and Sumardi (2017) revealed different perspectives that process innovation has a greater influence in increasing the competitiveness of a company’s business compared to other innovation strategy, namely product innovation and administrative innovation. In addition, Antunes et al. (2017) argued that companies that adopt strategies of process innovation get improvements in their performance, both operationally and financially, while product innovation only provides improvements in the financial performance of organizations.

2.3. TQM and Business Performance

TQM is an integrated business management strategy aimed at instilling quality awareness in all company processes (Swink et al., 2014). The International Standards Organization (ISO) defines TQM as a management approach for an organization, which is quality-centered, based on the participation of all its members and aims at long-term success through customer satisfaction and benefits for all members of the organization and also for society (ISO 8402: 1994). Today, TQM can be a major factor in achieving competitive advantage for companies. This is because the TQM concept allows organizations to run the company efficiently, improve employee productivity, materials and also improve product quality (Martínez-Costa et al., 2008).

In the past few decades, as has been demonstrated through many publications, TQM has a significant role in improving business performance because it affects the growth and performance of the company so that the company continues to achieve continuous improvement as an important integral part of its organizational strategy (Jonah et al., 2018). The relationship between TQM and performance has been investigated by many researchers on various types of performance, including financial performance, operational performance and quality performance.

Although the effects of TQM on various types of performance are inconsistent, quality performance generally shows a strong and positive relationship (Zehir et al., 2012). According to Deming, quality is the main determinant of the company’s success in a competitive business environment. Quality management is an activity that is increasingly important for all types of companies and is associated with corporate strategies to gain competitive advantage (López-Mielgo et al., 2009). Other researchers mentioned that some dimensions of TQM, especially those related to leadership and education, have a stronger correlation with business performance (Cetindere et al., 2014).

Thus, in this research, it is considered relevant the study of this issue since the study carried out previously showed contradictory results regarding relationship between innovation and TQM in business performance. The result of the study is expected to be used as feedback for companies related to the execution of their innovation strategies and TQM implementation promptly to improve their business performance. For academic interests, this research is expected to be used as empirical evidence regarding the influence of corporate innovation strategies and the implementation of TQM on business performance.

2.4. Proposed Framework and Research Hypotheses

The proposed framework in this study will focus on the business performance of the pharmaceutical industry in Indonesia which is related to innovation strategy and implementation of TQM based on literature and previous research are two important factors that plays an important role in supporting the company’s performance where the two variables are correlated to improve the company’s business performance.

In this research, the authors use the dimensions of product innovation, process innovation, administrative innovation and innovation management to measure innovation strategy. Those dimensions are based on previous research that product innovation and administrative innovation have a less significant influence on business performance so that it needs further investigation. Meanwhile, the constructs of TQM in the pharmaceutical
industry in this study are leadership management, continuous improvement, management commitment, supplier quality, customer orientation, employee involvement, and quality management systems. The determination of the seven dimensions is based on previous research, including Zehir et al. (2012), Kumar and Prasad (2017), also the unit of analysis in this research is the pharmaceutical industry which has strict rules related to the production process and the products produced must meet GMP regulations which tend to still have weaknesses in those seven dimensions.

Business performance will be measured based on the performance of business functions. Business performance is defined as performance that is part of the company’s business functions that support the company’s overall performance based on four perspectives namely financial, customer, internal business processes and learning and growth. Therefore, the performance of business functions must be aligned with the performance of the company so that the company can meet predetermined targets. One of the most popular approaches for measuring business performance is the balanced scorecard (BSC). BSC can capture both financial element and non-financial strategies of the company and discuss causal relationships that can improve business results (Muiruri and Kilia, 2015). Robert Kaplan and David Norton developed this approach for the first time. To establish a company’s future vision and provide a competitive advantage, financial data must be defined in intangible indicators (Lyibildire and Karasioglu, 2018).

Despite the previous studies showed the positive relationship between innovation strategy and TQM implementation, including Zehir et al. (2012). However, some researchers revealed different results, that TQM might be an inhibitor for innovation (Dinh et al., 2006). Therefore, it was considered relevant to investigate the relationship between innovation strategy and implementation of TQM. The study model is given in Figure 3.

Based on the model, three different hypotheses were formed:

$Q_1$ – Is there any relationship between innovation strategy and TQM implementation?

$H_{01}$: There is no significant relationship between innovation strategy and TQM implementation.

$H_1$: Innovation strategy and TQM implementation are interconnected with each other.

As described previously, several studies have shown innovation strategy gave a positive relationship to business performance (Al-Battaineh (2018) and Beyene et al. (2016). However, Riyadi and Sumardi (2017) revealed different perspectives that process innovation has a greater influence in increasing the competitiveness of a company’s business compared to another innovation strategy.

Thus, it is considered relevant to the analysis of this relationship based on the following hypotheses:

$Q_2$: What impact the adoption of innovation strategy might reflect on business performance?

$H_{02}$: The adoption of an Innovation strategy does not have a positive influence on business performance

$H_2$: The adoption of innovation strategy encourages the improvement of business performance.

Several studies were designed to investigate the relationship between TQM and business performance. Although the effects of TQM on various types of performance are inconsistent, quality performance generally shows a strong and positive relationship (Zehir et al., 2012). Other researchers revealed that TQM is positively associated with business performance such as financial and profitability (Nair and Choudhary, 2016). However, Cetindere et al. (2014) revealed a different perspective that dimensions of TQM related to leadership and education, have a stronger correlation with business performance compared to other dimensions. It is, therefore, necessary to analyze the relationship between TQM and business performance to clarify the issue, research hypotheses are defined as follows:

$Q_3$ – What impact TQM implementation might reflect on business performance?

$H_{03}$: The implementation of TQM does not reveal an improvement in their business performance

$H_3$: The implementation of TQM reveals an improvement in their business performance.

3. METHODS

This research is conducted at pharmaceutical companies in Indonesia and focused on the strategic management field that reviews the strategy of innovation and TQM implementation to improve the company’s business performance.
This research used a questionnaire survey method conducted during September-October 2019, through a descriptive and verification approach. The descriptive approach aims to obtain a description of the nature and characteristics of variables being studied related to the phenomenon happening in the object of study, to identify and analyze the relationships between variables. The verification research aims to test the hypothesis carried out through data collection (survey questionnaire). This study will be tested whether the innovation strategy and TQM have an influence on improving the business performance of pharmaceutical companies in Indonesia. Verification analysis was carried out using Partial Least Square Structural Equation Modeling (PLS-SEM). PLS is a method that can be used to analyze both reflective and formative constructs (Abdillah and Jogiyanto, 2015). In this study, business performance based on the balanced scorecard is a formative construct, while the innovation strategy and TQM are reflective constructs.

3.1. Sampling Method

The method of distributing questionnaires, using purposive sampling technique and quota sampling method, where non-random sampling previously determined by researchers with the following considerations: information needs for research and characteristics in the population. Sample criteria in this research are pharmaceutical companies in Indonesia that manufactured generic drugs and participated in providing drugs for JKN program. Quota sampling is set by determining sample represents at least fifty percent of the market share of the pharmaceutical industry that produced generic drugs and participated in providing drugs for the JKN program, the data obtained is expected to be relevant and represented the current situation of the pharmaceutical industry in Indonesia.

According to data from the Food and Drug Supervisory Agency and the Indonesian Ministry of Health, as of the second quarter of 2019 there were around 94 pharmaceutical companies producing generic drugs and participating as providers of drugs for the National Health Insurance Program (BPJS Kesehatan). Of these, 35 companies have market shares above 0.1%, while the rest have market shares between 0.00% - 0.09%.

3.2. Data Collection

Hair et al. (2017) stated that the minimum use of samples in the Partial Least Square (PLS) analysis is based on (a) ten times the size of the most formative indicators used to measure one latent variable, or (b) ten times the highest number of structural paths directed at certain latent variables in the structural model. The structural path indicator in this study is 3, thus the minimum PLS sample in this study is at least 30 companies.

The questionnaire was distributed using the online method. This method provided the benefit of being able to collect a lot of data in a short time.

Since this research measures the business performance based on business function, it is determined that respondents for each company are employees at the level of middle management to top management who are responsible for making decisions related to research variables, starting from assistant manager, section chief, manager, head of department, senior manager, general manager, and Director. Each company is represented by four respondents so that it is expected to be able to represent four perspectives of company performance based on a balanced scorecard, namely financial, customers, internal business processes, and learning growth.

3.3. Measurement

This research uses a 5 point rating scale, referring to the Likert Scale in general. The answers to each instrument with this Likert scale have gradations from very positive to very negative. The data obtained is then processed by the PLS-SEM (Partial Least Square-Structural Equation Modeling) using SmartPLS 3.0 software. First, researchers develop a descriptive analysis of the items, followed by an analysis of causal relationships using path analysis to explain direct and indirect influence between variables and to investigate the influence through a path diagram of the causal relationship between independent variables on the dependent variable. In this study, the descriptive analysis of each variable is divided into 5 categories of measurement results with the percentage of respondents’ answers as listed in the Table 2.

Following that, hypothesis test with the bootstrapping method to produce the statistical test used (t test). Significance value used is \( \alpha = 0.05 \). Lastly, it is proceeded to a correlation analysis between the constructs on the level of dimensions and indicators of each variable studied in this research.

A strong correlation between constructs and the question items and a weak relationship with other variables is a way to test the construct validity. Construct validity consists of convergent validity and discriminant validity. Convergent validity is achieved if construct indicators have high correlations and have sufficient loading scores. Not only in loading scores, but validity is also shown by the convergence of all construct indicators. According to Vincenzo et al. (2010) the rule of thumb used for convergent validity is outer loading \( > 0.7, 0.5 \) and Average Variance Extracted (AVE) \( > 0.5 \).

Meanwhile, according to Hair et al. (2017), the loading value \( \geq 0.5 \) is considered significant. Reliability tests are in line with construct validity used to measure the consistency of respondents in answering question items in questionnaires or research instruments (quantitative). We used composite reliability (CR) to measure reliability since it measures the true reliability value of a construct (Abdillah and Jogiyanto, 2015) According to Hair et al. (2017). Rule of thumb alpha value of Composite reliability must be greater than 0.7 although the value of 0.6 is still acceptable. For all the measures, both indices are higher than the evaluation criteria of 0.5 for the loading value and AVE and 0.7 for composite reliability (see Table 3).

As stated before, the business performance variable (Y) is a formative construct. Parameters to assess its convergent validity using an outer weight of each indicator compared to one another to determine which indicator gives the biggest contribution in one construct and VIF (variance inflation factor) to
Table 2: Interval value categories

<table>
<thead>
<tr>
<th>Range of Scores</th>
<th>Innovation Strategy ($X_1$)</th>
<th>TQM ($X_2$)</th>
<th>Business Performance ($Y$)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.00 - 1.79</td>
<td>Very Ineffective</td>
<td>Very bad</td>
<td>Very Low</td>
</tr>
<tr>
<td>1.80 - 2.59</td>
<td>Ineffective</td>
<td>Bad</td>
<td>Low</td>
</tr>
<tr>
<td>2.60 - 3.39</td>
<td>Quite effective</td>
<td>Fair</td>
<td>Fair</td>
</tr>
<tr>
<td>3.40 - 4.19</td>
<td>Effective</td>
<td>Good</td>
<td>High</td>
</tr>
<tr>
<td>4.20 - 5.00</td>
<td>Very effective</td>
<td>Very good</td>
<td>Superior/outstanding</td>
</tr>
</tbody>
</table>

Table 3: PLS Test Parameter

<table>
<thead>
<tr>
<th>Model Test</th>
<th>PLS-SEM Output</th>
</tr>
</thead>
<tbody>
<tr>
<td>Outer model (structural test)</td>
<td>Convergent Validity (loading factor/AVE/outer weight,VIF)</td>
</tr>
<tr>
<td></td>
<td>Discriminant Validity (Cross loading factor)</td>
</tr>
<tr>
<td></td>
<td>Composite reliability</td>
</tr>
<tr>
<td>Inner model (measurement test)</td>
<td>R Square ($R^2$)</td>
</tr>
<tr>
<td></td>
<td>T statistic Test (estimated path coefficient)</td>
</tr>
</tbody>
</table>

Source: Abdillah & Jogiyanto, 2015

quantify the severity of multicollinearity between formative indicators. High correlation is not expected between formative indicators since the indicator’s informative models are not interchangeable. VIF < 5 indicates no critical levels of collinearity (Hair et al., 2017). Both outer weight and VIF value meets the specification (see Table ??)

Discriminant validity is achieved not only when the loading score meets the criteria but also indicated by correlation discrimination (cross-loading value), it means that each indicator loading should be greater than all of its cross-loadings. It is found that the value of the loading factor indicator for all intended indicators has the highest value compared to the value of the loading factor for the other dimensions. For example, the loading factor value of indicator Y.35 (for learning Growth dimension) has the highest loading factor value, which is 0.738 compared to the value of the other dimension loading factor. Thus, the value of the correlation indicator in a variable is better than the indicator for other variables, meaning that our research model meets discriminant validity.

The relationship between innovation strategy variables ($X_1$) and TQM ($X_2$) to the construct is a manifest indicator (reflective), whereas the relationship of business performance indicators ($Y$) to the construct is a formative indicator and those were second-order construct / higher-order construct (HOC) model. One of the advantages of PLS compared to other analytical methods is being able to measure formative and reflective constructs in one research model. Previous researchers used several approaches to specify and estimate the reflective-formative higher-order construct (HOC) model in PLS-SEM, namely the repeated indicators approach and the two-stage approach (extended repeated indicator approach). The results showed that the indicator repetition approach produced a smaller bias in estimating the higher-order construct measurement model, namely the relationship between the lower and higher-order components. In contrast, the two-stage approach shows better recovery parameters in path analysis 1) exogenous constructs to HOC, and 2) from HOC to endogenous constructs in the path model (Sarstedt et al., 2019).

To validate the overall model, the Goodness of Fit (GoF) parameter is used. GoF index is a single measurement used to validate the performance combination of the measurement model (outer model) and structural model (inner model). According to Abdillah and Jogiyanto (2015), the value of the GoF Index is derived from the roots of the average communalities index multiplied by the average of the R2 model. GoF values have a range between 0-1, with a classification of small GoF values at 0.1, moderate GoF at 0.25, and a substantial GoF value at 0.36.

4. RESULTS AND DISCUSSION

Based on questionnaire results received back from managers working in the pharmaceutical industry producing generic drugs and participating in providing drugs for the JKN program during September-October 2019 period, there were 42 pharmaceutical companies with a total of 168 respondents who filled the questionnaire and represented a total market share of generic drugs manufacturers of 77.15% which means have met the specified quota sampling requirements, which represent a minimum of 50% of the market share of the generic drug industry and a minimum of 30 companies.
Table 4: Descriptive analysis result

<table>
<thead>
<tr>
<th>No.</th>
<th>Variable</th>
<th>Dimension</th>
<th>Average Respondent Perception</th>
<th>Category</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Innovation Strategy</td>
<td>Product Innovation (IPd)</td>
<td>3.56</td>
<td>Effective</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Process Innovation (IPr)</td>
<td>4.02</td>
<td>Effective</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Administrative innovation (IA)</td>
<td>3.76</td>
<td>Effective</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Manajemen Inovasi (X1.4)</td>
<td>3.76</td>
<td>Effective</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Average of Innovation Strategy</strong></td>
<td><strong>3.78</strong></td>
<td><strong>Effective</strong></td>
</tr>
<tr>
<td>2</td>
<td></td>
<td>Leadership management (MK)</td>
<td>4.04</td>
<td>Good</td>
</tr>
<tr>
<td></td>
<td>TQM</td>
<td>Continuous improvement (PB)</td>
<td>3.87</td>
<td>Good</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Management commitment (KM)</td>
<td>3.81</td>
<td>Good</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Supplier quality (KP)</td>
<td>3.8</td>
<td>Good</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Customer orientation (OP)</td>
<td>3.88</td>
<td>Good</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Employee involvement (KK)</td>
<td>3.89</td>
<td>Good</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Management quality system (SMK)</td>
<td>4.1</td>
<td>Good</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Average of TQM</strong></td>
<td><strong>3.95</strong></td>
<td><strong>Good</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Financial (KF)</td>
<td>3.69</td>
<td>High</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Customer(KC)</td>
<td>3.4</td>
<td>High</td>
</tr>
<tr>
<td>3</td>
<td>Business Performance</td>
<td>Internal Business Process (KI)</td>
<td>3.98</td>
<td>High</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Learning and Growth (KL)</td>
<td>3.73</td>
<td>High</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Average of Business Performance</strong></td>
<td><strong>3.7</strong></td>
<td><strong>High</strong></td>
</tr>
</tbody>
</table>

*Source: Research calculations*
The result (see Table 4 shows that respondents’ perceptions about innovation strategy viewed based on the dimensions of product innovation, process innovation, administrative innovation, and innovation management are in the effective category with an average value of 3.78. Respondents’ perceptions related to the implementation of TQM which were assessed based on the dimensions of Leadership Management, Management Commitment, Supplier Quality, Customer Orientation, Continuous Improvement, Employee Involvement, and Quality Management System are well implemented (good category) with an average value of 3.95, whereas respondents’ perceptions about business performance viewed based on the dimensions of financial, customer, internal business process and learning and growth performance are in the high category with average value 3.70. Table 5 is the result of the path coefficient analysis with the Higher Order Construct - standard repeated indicator approach.

The Table 5 is the result of the path coefficient analysis with the Higher-Order Construct - standard repeated indicator approach. R square is the best indicator of the explanatoriness degree of the regression model. Here, a 99.6% linear correlation was found between R square the dependent variable (business performance), and the independent variable (innovation strategy and TQM). This means that 99.6% of the business performance variable is explained by the innovation strategy and TQM variable.

Table 6 presents the correlation matrix of all variables. It shows a high degree of significant correlation between innovation strategy and TQM, innovation strategy and business performance, and TQM and business performance (correlation is significant at 0.05 level, p values ; 0.05, T statistics ; 1.96). The direction of the positive relationship is indicated by the positive original sample value. The significant correlation between innovation strategy, TQM and business performance confirms our study’s hypotheses.

The present study sought to analyze the relationship between innovation strategy and TQM in improving the business performance of the Pharmaceutical Industry in Indonesia. Survey results show that the execution of innovation strategy is in the effective category with an average value of 3.78, TQM is well implemented (good category) with an average value of 3.95, whereas business is in the high category with an average value of 3.70. This indicates that the pharmaceutical industry in Indonesia has good awareness in responding to business landscape changes since JKN implementation in 2014 which is to manufacture drugs with low cost and low margin.

In terms of our hypotheses (Table 6) findings for H1 (Innovation strategy on TQM) confirm that implementation of the TQM system in a company interconnected with the Innovation strategy. This supports the findings of prior researches (Hung et al., 2011) that TQM implementation significantly gives a positive impact on innovation strategy in a company. One of the TQM dimensions, continuous improvement will provide an environment for the company to make innovation in order to meet customer needs and expectations.

The next results for hypothesis H2 (Innovation strategy Business Performance) show that there is a positive correlation between those variables in all dimensions. This finding aligns with previous studies regarding the role of innovation strategy on the company’s business performance in various dimensions (Al-Battaineh (2018) and Antunes et al. (2017).

The further result shows that innovation management and product innovation give a bigger impact statistically (in terms of loading factor and R square) to innovation strategy compared to process innovation and administrative innovation. This proves the important role of innovation management in pharmaceutical companies in formulating corporate innovation strategies is in line with the company’s vision and right on target. Some pharmaceutical companies in Indonesia have specialized departments that manage corporate innovation programs, called corporate planning strategy. The department’s responsibilities include analyzing business trends (e.g. changes in the company’s strategic focus, merger acquisition opportunities), analyzing opportunities and threats both internal and external to develop new ideas, new products/services/processes, those are then used as work programs in the RD Department.

The results also support the findings of previous researchers (Simani and Kenyatta (2017), Simani and Kenyatta (2017), and Hassan et al. (2012)) who revealed clear evidence for the concept that companies that implemented TQM reveal an improvement in their business performance (in terms of financial and non-financial aspect). Leadership management (loading factor= 0.914, R Square of 0.836) shows the biggest contribution to TQM implementation statistically. This proves that the role of the leader in the implementation of TQM is very important, one of the examples is in terms of communicating a quality culture to all employees in the company.

Several previous studies have been conducted and look into these dimensions, however, we believe the findings of this research formulate a number of important additions to the existing literature by fill a gap concerning some disagreements identified in previous investigations both of the ambiguity of the findings also concerning the different interpretations of the concepts studied. This research had the particularity to analyze the variable of innovation strategy in various dimensions, it was considered product innovation, process innovation, administrative innovation, and management innovation. Regarding the TQM, this research analyzed this variable through leadership management, continuous improvement, management commitment, supplier quality, customer orientation, employee involvement, and quality management systems. For business performance, this research analyzed this dimension based on the balanced scorecard concept, namely financial, customer, internal business process, and learning growth perspective. This research also provides a unique contribution to the analysis of the inter-dependencies between innovation strategy and TQM in improving business performance in Indonesian Pharmaceutical companies. Thus it will have strategic implications for the company and expect to be used as feedback related to the execution of their innovation strategies and TQM implementation promptly to improve their business performance.
Table 5: Construct Measurement summary: Coefficient path analysis and Reliability (Innovation strategy and TQM)

<table>
<thead>
<tr>
<th>No</th>
<th>Construct</th>
<th>Loading factor</th>
<th>AVE</th>
<th>Composite Reliability</th>
<th>R Square</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><strong>Innovation Strategy (X&lt;sub&gt;1&lt;/sub&gt;)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>Product Innovation (IPd)</td>
<td>0.906</td>
<td>0.664</td>
<td>0.836</td>
<td>0.821</td>
</tr>
<tr>
<td>2</td>
<td>Process Innovation (Ipr)</td>
<td>0.895</td>
<td>0.563</td>
<td>0.901</td>
<td>0.802</td>
</tr>
<tr>
<td>3</td>
<td>Administration innovation (IA)</td>
<td>0.805</td>
<td>0.819</td>
<td>0.887</td>
<td>0.648</td>
</tr>
<tr>
<td>4</td>
<td>Innovation Management (MI)</td>
<td>0.918</td>
<td>0.739</td>
<td>0.919</td>
<td>0.843</td>
</tr>
<tr>
<td></td>
<td><strong>TQM (X&lt;sub&gt;2&lt;/sub&gt;)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>Management Commitment (KM)</td>
<td>0.818</td>
<td>1.000</td>
<td>1.000</td>
<td>0.669</td>
</tr>
<tr>
<td>2</td>
<td>Supplier Quality (KP)</td>
<td>0.743</td>
<td>0.731</td>
<td>0.844</td>
<td>0.552</td>
</tr>
<tr>
<td>3</td>
<td>Employee involvement (KK)</td>
<td>0.703</td>
<td>1.000</td>
<td>1.000</td>
<td>0.495</td>
</tr>
<tr>
<td>4</td>
<td>Leadership Management (MK)</td>
<td>0.914</td>
<td>0.822</td>
<td>0.902</td>
<td>0.836</td>
</tr>
<tr>
<td>5</td>
<td>Customer orientation (OP)</td>
<td>0.830</td>
<td>0.674</td>
<td>0.805</td>
<td>0.688</td>
</tr>
<tr>
<td>6</td>
<td>Continuous improvement (PB)</td>
<td>0.860</td>
<td>1.000</td>
<td>1.000</td>
<td>0.740</td>
</tr>
<tr>
<td>7</td>
<td>Quality Management system (SMK)</td>
<td>0.802</td>
<td>1.000</td>
<td>1.000</td>
<td>0.363</td>
</tr>
</tbody>
</table>

R Square Business Performance (Y) = 99.6% (strong model) ; GoF Index = 0.690 (Substantial)

Table 6: Correlation Analysis (PLS-Bootstrapping’s result)

<table>
<thead>
<tr>
<th>No</th>
<th>Variable correlation</th>
<th>Original Sample (O)</th>
<th>Sample Mean (M)</th>
<th>T</th>
<th>Statistics (—O/STDEV—)</th>
<th>P Values</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Innovation Strategy (X1) à TQM (X2)*</td>
<td>0.8180</td>
<td>0.8170</td>
<td>32.2970</td>
<td>0.000</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>Innovation Strategy à Business Performance (Y)**</td>
<td>0.4360</td>
<td>0.4400</td>
<td>7.1010</td>
<td>0.000</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>TQM (X2) à Business Performance (Y)</td>
<td>0.4890</td>
<td>0.4850</td>
<td>7.1370</td>
<td>0.000</td>
<td></td>
</tr>
</tbody>
</table>

*Analysis using standard indicator approach
**Analysis using Extended repeated indicator approach (two stage approach)
Two tailed test, level of significance : 95%
5. CONCLUSION

This study examines the relationship between innovation strategy, TQM and business performance. A proposed model comprises four types of innovation strategy, seven TQM practices, and four perspectives to measure business performance. To test the proposed model, data were collected from a sample of Indonesian pharmaceutical companies that represent at least fifty percent of the market share of the pharmaceutical industry that produced generic drugs and participated in providing drugs for the JKN program. The results of the analysis show that innovation strategies and TQM practices are interconnected and both innovation strategy and TQM can improve a company’s business performance in all dimensions. In particular, the results indicate management innovation has the biggest contribution to the company’s innovation strategy and leadership management has the biggest impact on TQM implementation.

Limitations of this study should be recognized to provide researchers with future research opportunities. First, respondents for this study are Indonesian pharmaceutical companies that manufactured generic drugs and participated in providing drugs for the JKN program. The firms fit the research purpose because they are affected by JKN implementation. However, other pharmaceutical firms, that did not manufacture generic drugs might have been left out of this study, whereas they could be more innovative. It would be promising to replicate this research using data collected from firms that produced both generic and branded products. Further, it may not be possible to generalize our findings for firms that are not manufactured generic products, since our data involves only generic manufacturers firms, the findings of this study may not be applicable to non-generic manufacturer firms. Future studies could be conducted to examine the relationship between innovation strategy and TQM practices in both generic product manufacturer firms and branded product manufacturer firms. Second, it would be worthwhile to consider conducting case studies to get an in-depth insight on how innovative and TQM-driven firms improve their business performance and why management innovation is contributed the most important in executing innovation strategy and leadership management is the most important among TQM practices.

References

URL: https://doi.org/10.1016/j.sbspro.2012.11.109

URL: https://doi.org/10.1108/02656710610704230
URL: https://www.sciencedirect.com/science/article/pii/S096959311000085S
URL: https://www.semanticscholar.org/paper/An-Empirical-Assessment-of-Service-Quality-and-its-Hassan-Malik/a58bcd3f920ad92ddc435de033c8ed5d4a2470877
URL: https://www.sciencedirect.com/science/article/pii/S096959311000085S
URL: http://www.kalbe.co.id/Portals/0/pdf/annual-report_KLBFR2017_FINAL.pdf
URL: https://doi.org/10.1016/j.jom.2012.02.003
DOI: 10.1016/j.jom.2012.02.003
URL: https://www.sciencedirect.com/science/article/pii/S016644970900042X
DOI: https://doi.org/10.1016/j.technovation.2009.02.005
URL: https://www.sciencedirect.com/science/article/pii/S0925527310003088
DOI: https://doi.org/10.1016/j.ijpe.2007.02.046

URL: https://doi.org/10.1108/IJOPM-03-2012-0098


URL: http://pasca.unhas.ac.id/ojs/index.php/hebr/article/view/1189


URL: https://doi.org/10.1016/j.ausmj.2019.05.003


URL: https://doi.org/10.1016/j.asmg.2017.11.002
